FTC Shouldn't See Aggrenox Docs, Boehringer Tells DC Circ.
Documents sought by the Federal Trade Commission on Boehringer Ingelheim's 2008 patent dispute settlement with Barr Pharmaceuticals over the drug Aggrenox should remain hidden from the agency because they reflect legal...To view the full article, register now.
Already a subscriber? Click here to view full article